Autres langues

12/08 HLS Therapeutics : Q2 2026 Conference Call Presentation
12/08 HLS Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08 Earnings Flash (HLS.TO) HLS Therapeutics Inc. Reports Q2 Revenue $14.7M, vs. FactSet Est of $14.2M
12/08 HLS Therapeutics Announces Q2 2026 Financial Results
12/08 HLS Therapeutics Inc. Reaffirms Consolidated Earnings Guidance for 2026
05/08 HLS Therapeutics Provides Update on NILEMDO™ Market Access
29/07 HLS Therapeutics to Host Q2 2026 Financial Results Conference Call
26/06 HLS Therapeutics Reports Annual Meeting Results
23/06 HLS Therapeutics Inc. announces an Equity Buyback for 1,500,000 shares.
23/06 HLS Therapeutics to Begin its Normal Course Issuer Bid
23/06 HLS Therapeutics Announces Normal Course Issuer Bid
23/06 HLS Therapeutics Inc. authorizes a Buyback Plan.
15/05 HLS Therapeutics : First Quarter 2026 Presentation
15/05 HLS Therapeutics Q1 Net Loss Narrows on Lower Costs, Higher Revenue
15/05 Earnings Flash (HLS.TO) HLS Therapeutics Says Vascepa Net Sales Grew 15% In Q1, Strongest Quarterly Growth Since Q2 2025
15/05 Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on March 13, 2025.
15/05 HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
15/05 HLS Therapeutics 2026 Financial Guidance Reaffirmed; Revs of US$56-60M and Adjusted EBITDA of $18.5-21M
15/05 HLS Therapeutics Cites NILEMDO Full Commercial Launch in April
15/05 HLS Therapeutics Q1 2026 Revenue of US$12.9 million, up 2% YoY
15/05 HLS Therapeutics Announces Q1 2026 Financial Results
15/05 HLS Therapeutics Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2026
01/05 HLS Therapeutics to Host Q1 2026 Financial Results Conference Call
23/04 HLS Therapeutics : Investor Presentation
14/04 HLS Therapeutics to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Aucun résultat pour cette recherche